OBIO
Company Description
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 33.48M | 2.64M | 2.76M | 3.53M | (782,000) | 5.70M |
| Net Income | (52.70M) | (61.02M) | (49.12M) | (33.61M) | (23.01M) | (21.36M) |
| EPS | -1.11 | -1.66 | -1.48 | -1.32 | -0.02 | -0.01 |
| Free Cash Flow | (49.45M) | (50.85M) | (46.20M) | (29.88M) | (19.70M) | (26.72M) |
| FCF / Share | -1.04 | -1.38 | -1.39 | -1.17 | -0.96 | -1.31 |
| Operating CF | (48.96M) | (50.56M) | (46.13M) | (29.29M) | (19.43M) | (26.18M) |
| Total Assets | 114.86M | 76.17M | 95.21M | 95.57M | 13.53M | 38.09M |
| Total Debt | 15.96M | 16.53M | 1.69M | 11.87M | 5.67M | 9.46M |
| Cash & Equiv | 34.69M | 22.26M | 30.56M | 19.78M | 9.94M | 20.34M |
| Book Value | 63.38M | 32.96M | 68.04M | 52.53M | (71.23M) | (48.54M) |
| Return on Equity | -0.83 | -1.85 | -0.72 | -0.64 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88,000 | 110,000 | 30.92M | 861,000 | 836,000 | 868,000 | 253,000 | 987,000 | 778,000 | 620,000 | 262,000 | 419,000 |
| Net Income | (23.75M) | (20.69M) | 6.25M | (20.83M) | (19.36M) | (18.75M) | (16.16M) | (15.43M) | (15.98M) | (13.46M) | (12.82M) | (13.32M) |
| EPS | -0.38 | -0.33 | 0.12 | -0.40 | -0.50 | -0.49 | -0.42 | -0.41 | -0.45 | -0.38 | -0.36 | -0.38 |
| Free Cash Flow | (19.59M) | (22.35M) | (2.30M) | (14.86M) | (15.56M) | (16.73M) | (13.64M) | (13.77M) | (10.31M) | (13.12M) | (10.97M) | (10.30M) |
| FCF / Share | -0.31 | -0.36 | -0.05 | -0.28 | -0.41 | -0.44 | -0.36 | -0.37 | -0.29 | -0.37 | -0.31 | -0.29 |
| Operating CF | (19.33M) | (22.17M) | (2.27M) | (14.55M) | (15.53M) | (16.62M) | (13.54M) | (13.70M) | (10.21M) | (13.11M) | (10.97M) | (10.28M) |
| Total Assets | 115.70M | 100.66M | 114.86M | 104.81M | 42.83M | 59.05M | 76.17M | 75.32M | 72.38M | 82.63M | 95.21M | 116.36M |
| Total Debt | 21.77M | 33.63M | 32.44M | 16.04M | 16.35M | 16.44M | 16.53M | 1.84M | 1.45M | 1.62M | 1.69M | 11.46M |
| Cash & Equiv | 20.47M | 28.37M | 34.69M | 42.01M | 18.75M | 18.35M | 22.26M | 25.61M | 23.71M | 23.32M | 30.56M | 19.08M |
| Book Value | 29.42M | 50.97M | 63.38M | 43.74M | 295,000 | 16.86M | 32.96M | 46.22M | 44.12M | 57.19M | 68.04M | 79.66M |
| Return on Equity | -0.81 | -0.41 | 0.10 | -0.48 | -65.64 | -1.11 | -0.49 | -0.33 | -0.36 | -0.24 | -0.19 | -0.17 |
